Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Prostate Cancer Metastatic|Neuroendocrine Tumors
DRUG: Pembrolizumab|DRUG: Lenvatinib
Radiologic Progression Free Survival (rPFS) for soft tissue lesions, For soft tissue lesions, rPFS is defined as the date of treatment intiation to date of radiologic progression of soft tissue lesions per RECIST 1.1 or death whichever occurs first., 2 years|Radiologic Progression Free Survival (rPFS) for bone lesions, For bone lesions, rPFS is defined as the date of treatment initiation to date of progression of bone lesions per PCWG3 criteria or death whichever occurs first., 2 years
Frequency and Severity of adverse events, Frequency and severity of adverse events as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., 2 years|Overall Survival (OS), Overall survival (OS) will be measured from date of registration to date of death from any cause., 2 years|Objective Response Rate (ORR), ORR will be the proportion of patients achieving either a complete response or a partial response, 2 years|Duration of Response (DoR), DOR will be measured from the start date of the best response achieved until the date of relapse, 2 years
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.